KRAS and metastatic malignant neoplasm: KRAS mutations are sufficient to initiate premalignant lesions, PanINs; PanINs can progress to locally invasive or metastatic cancer by way of either genomic rearrangements or stepwise acquisition of mutations in suppressor genes (CDKN2A, TP53 and SMAD4).